Response-Guided Strategy Investigates Omission of Repeat TUR in High-Risk NMIBC.
Can repeat TUR be skipped in T1 #NMIBC? @RobertoContieri@istitutotumori, joins @UroDocAsh@UTMDAnderson to discuss the HuNIRe trial. A response-guided approach spared 71% of patients re-TUR, with no upstaging to MIBC and similar RFS and PFS. #WatchNow > bit.ly/4seZn7A
🇮🇹 Gli Azzurri are coming for the Uromigos World Cup! ⚽🏆
From the Duomo di Milano to the latest in bladder preservation, Team Italy is bringing the Milan criteria for clinical complete response to the pitch.
And they've got a message for the competition: We're coming for you! 👀
🎥 : @giannatempopatr & @CMercinelli | #UromigosLive
Premio Rising Star, destinato a tre giovani e promettenti urologi Under 33 che abbiano dimostrato caratteristiche qualitative di rilievo in ambito scientifico, afferenti alle seguenti macroaree: nord in memoria di Paolo Bianchi, centro in memoria di Giorgio Martino e sud in memoria di Davide Loizzo.
Vincitore nord: Luca Afferi
Affiliazione: Kantonsspital Aarau, Svizzera
Vincitore nord: Luigi Nocera
Affiliazione: ASST Spedali Civili, Brescia
Vincitore centro: Antonio Grosso
Affiliazione: Azienda Ospedaliero Universitaria Careggi, Firenze
Vincitore sud: Roberto Contieri
Affiliazione: IRCCS Istituto Nazionale Tumori — Fondazione “G. Pascale”, Napoli
#Urologia#SIU26
Congratulations to @LauraBukavinaMD@jaymsiva@drjkaouk and @ClevelandClinic team on largest external validation of the IBCG IR NMIBC substratification model
📊 2822 patients | 20 years | 3-year recurrence by subgroup:
🟢 IR-low: 12%
🟡 IR-intermediate: 38%
🔴 IR-high: 77%
Progression followed the same stepwise pattern. Fine-Gray competing-risk models confirmed significance (p<0.001) - separation held on 12-month landmark analysis, ruling out early-event bias.
Yet more evidence that trials enrolling IR NMIBC should stratify by IBCG subgroup at enrollment to be clinically meaningful.
Conflating patients with 12% and 77% recurrence risk in the same trial arm is a fundamental problem.
Full text:
authors.elsevier.com/sd/arti…@IBCG_BladderCA
A multi-center study examines maintenance schedules for intermediate-risk #NMIBC. @RobertoContieri@IstTumori joins @UroDocAsh@UTMDAnderson to discuss the results which include two-year recurrence-free survival of 55% with no maintenance versus 78% with any maintenance. Classification and regression tree analysis identified optimal cutoff at more than six monthly instillations. #WatchNow on UroToday > bit.ly/3OEHP5m
1) Approval based on marginal improvements in efficacy (without improvement to CSS/OS)
2) Toxicity that isn't G5 (death) doesn't seem to impact approval. 10-15% serious autoimmune AEs in NMIBC is deemed ok
3) little weight given to efficacy vs toxicity balance of a drug
Excellent lecture by @SScagliarini_ on the growing importance of patient-reported outcomes in oligometastatic RCC. A crucial reminder that beyond oncologic endpoints, understanding the patient perspective is essential to truly optimize treatment strategies.
@Synergy_Uro@Uroweb
Great pleasure having Prof. Axel Bex at @Synergy_Uro discussing the evolving landscape of locally advanced RCC. Excellent insights and stimulating discussion on current challenges and future directions in kidney cancer care. @eau_yuo@EAUYAU_RenalCa@UrowebESU@EAU_Uroonco